Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo.

Skip to main content

Open Access Publications from the University of California

Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo.

2020

Author(s): Mobasher, P
Guerra, R
Li, SJ
Frangos, J
Ganesan, AK
Huang, V
et al.

Published Web Location

https://doi.org/10.1111/bjd.18606

Main Content